BioSpace News Archive

Monte Nido & Affiliates - the nation’s leading provider of eating disorder treatment for over twenty-four years - announces the opening of Monte Nido Chicago on March 2, 2020 in Winfield, IL.

The Medical College of Wisconsin has expanded its MCW-Central Wisconsin campus located in Wausau to a larger space.

Christopher Fanning leads commercial markets; Christine Reiten joins as VP of Medicaid; John Warren overseeing Medicare portfolio

As part of the biopharmaceutical industry’s commitment to advance diversity and inclusion in the workplace, president and chief executive officer Stephen J. Ubl of the Pharmaceutical Research and Manufacturers of America signed the CEO Action for Diversity & Inclusion Pledge.

A Conversation with the Women of Steinberg Diagnostic Medical Imaging (SDMI) is an influential video series where a diverse group of powerful women came together to discuss their opinions on healthcare, business and women.

Following a priority review, Health Canada has approved Cablivi® for the treatment of adults with acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy.

ProPath, the largest 100% physician-owned pathology practice in the United States, announced that New England Tissue Issue, a dermatopathology practice in Fall River, MA, has joined the ProPath family of companies.

MetroPlus Health Plan today announced the appointment of Julie Myers, M.D., M.P.H., as the City’s public option health plan’s new Associate Medical Director, assuming a leadership role in the plan’s Partnership in Care (PIC) Special Needs Plan, serving HIV-positive, transgender, and homeless New Yorkers and their families. Her appointment was effective Monday, February 3.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today that Jeanne Regnante, a long-time healthcare and global patient engagement professional, has joined the Foundation as Chief Health Equity and Diversity Officer.

Shanghai Junshi Biosciences Co., Ltd. (“the Company,” HKEX: 1877), an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs with clinical research and commercialization on a global scale, today reported key financial results for the year 2019.